Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Michaela Barbier, Nicholas Durno, Craig Bennison, Mathias Örtli, Christian Knapp, Matthias Schwenkglenks
| Year of publication: |
2022
|
|---|---|
| Authors: | Barbier, Michaela ; Durno, Nicholas ; Bennison, Craig ; Örtli, Mathias ; Knapp, Christian ; Schwenkglenks, Matthias |
| Published in: |
The European journal of health economics. - Berlin : Springer, ISSN 1618-7601, ZDB-ID 2011428-X. - Vol. 23.2022, 5, p. 837-846
|
| Subject: | Chronic lymphocytic leukemia | Cost-effectiveness | EVPI | Partitioned survival model | Rituximab | Venetoclax | Schweiz | Switzerland | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Chronische Krankheit | Chronic disease |
| Type of publication: | Article |
|---|---|
| Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
| Language: | English |
| Other identifiers: | 10.1007/s10198-021-01398-7 [DOI] |
| Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10013279318